New hope for hard-to-treat brain lymphoma: cell therapy trial launches
NCT ID NCT07062627
First seen Dec 26, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This study tests a new treatment called Anbal-cabtagene autoleucel (Anbal-cel) for people with a type of lymphoma that affects the brain or spinal cord and has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells, which are collected, modified in a lab, and then given back to fight the cancer. The study will enroll 12 adults and monitor them closely for at least 12 months to see if the treatment is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.